Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
Fesharaki-Zadeh A, Lowe N, Arnsten A. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports 2023, 3: 100154. DOI: 10.1016/j.nerep.2022.100154.Peer-Reviewed Original ResearchN-acetylcysteineCognitive deficitsΑ2A-adrenoceptor agonistsPrefrontal cortexCOVID19 infectionPlacebo-controlled trialOpen-label treatmentCommon side effectsExecutive functionPFC connectionsBrain fogAcid blockadeLabel treatmentHypotensive episodesGuanfacine treatmentNMDA receptorsPatient brieflySide effectsClinical experienceGuanfacineCognitive impairmentPatientsPrefrontal connectivityDemonstrate efficacyPrefrontal function